MARKET NEWS

Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers
NJIT Researchers Unlock a New Method for Testing Protein-Based Drugs
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613 in Combination With Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Cara Therapeutics Announces Difelikefalin Injection NDA Has Been Submitted in Japan
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate
SCHOTT Pharma Expands Cartridge Production in China & Hungary

  FEATURED EDITORIAL


  COMPANY PROFILE

Artcraft Health is a leading patient engagement and education agency that takes a holistic approach to demonstration device development and training. Our goal is to elevate and support the entire patient experience through educational onboarding initiatives involving both clinicians and patients. This is how we ensure certainty of use and long-term success. We help patients, caregivers, clinicians, and healthcare providers–who are either counseling patients or adopting new therapies and drug delivery methods–to build the skills, knowledge, and motivation they need for a successful outcome. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Spectradyne Launches New ARC Particle Analyzer

Spectradyne Launches New ARC Particle Analyzer

Spectradyne recently launched its second-generation product, the ARC particle analyzer. Spectradyne’s ARC is a ground-breaking technology for analyzing biological nanoparticles in complex….

BD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Research

BD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Research

BD (Becton, Dickinson and Company) recently launched BD® Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher….

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing & Sourcing Powerhouse

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing & Sourcing Powerhouse

Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, recently made its debut…..

Wheeler Bio Announces President & Chief Operating Officer 

Wheeler Bio Announces President & Chief Operating Officer 

Wheeler Bio, a new CDMO specializing in the cell line development, process development, and small batch clinical production of antibodies, has announced the appointment of….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 12 – Capsules
October 19 – Analytical Testing